# Neeraj Agarwal

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/neeraj-agarwal/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,971 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 66 |
| i10-index | 263 |
| Last Known Institution | Jaypee Institute of Information Technology |
| OpenAlex ID | https://openalex.org/A5100763587 |
| ORCID iD | 0000-0003-1076-0428 |
| Works | 1,045 |

## Researcher papers

- [Olaparib for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/olaparib-for-metastatic-castration-resistant-prostate-cancer/)
- [Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study](https://scholariq.org/papers/clinical-impact-of-covid-19-on-patients-with-cancer-ccc19-a-cohort-study/)
- [Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer](https://scholariq.org/papers/apalutamide-for-metastatic-castration-sensitive-prostate-cancer/)
- [Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/survival-with-olaparib-in-metastatic-castration-resistant-prostate-cancer/)
- [Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/kidney-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors](https://scholariq.org/papers/trophy-u-01-a-phase-ii-open-label-study-of-sacituzumab-govitecan-in-patients/)
- [Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/talazoparib-plus-enzalutamide-in-men-with-first-line-metastatic-castration/)
- [Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study](https://scholariq.org/papers/apalutamide-in-patients-with-metastatic-castration-sensitive-prostate-cancer/)
- [Kidney Cancer](https://scholariq.org/papers/kidney-cancer/)
- [Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/circulating-tumor-cell-counts-are-prognostic-of-overall-survival-in-swog-s0421-a/)
- [NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024](https://scholariq.org/papers/nccn-guidelines-insights-kidney-cancer-version-2-2024/)
- [Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial](https://scholariq.org/papers/niraparib-and-abiraterone-acetate-plus-prednisone-for-hrr-deficient-metastatic/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Jaypee Institute of Information Technology](https://scholariq.org/institutions/jaypee-institute-of-information-technology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.